GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HAEMATO AG (XTER:HAEK) » Definitions » Capex-to-Revenue

HAEMATO AG (XTER:HAEK) Capex-to-Revenue : 0.00 (As of Jun. 2023)


View and export this data going back to 2005. Start your Free Trial

What is HAEMATO AG Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

HAEMATO AG's Capital Expenditure for the six months ended in Jun. 2023 was €-0.37 Mil. Its Revenue for the six months ended in Jun. 2023 was €133.64 Mil.

Hence, HAEMATO AG's Capex-to-Revenue for the six months ended in Jun. 2023 was 0.00.


HAEMATO AG Capex-to-Revenue Historical Data

The historical data trend for HAEMATO AG's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HAEMATO AG Capex-to-Revenue Chart

HAEMATO AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.01 - - -

HAEMATO AG Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.01 -

Competitive Comparison of HAEMATO AG's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, HAEMATO AG's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HAEMATO AG's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HAEMATO AG's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where HAEMATO AG's Capex-to-Revenue falls into.



HAEMATO AG Capex-to-Revenue Calculation

HAEMATO AG's Capex-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-1.089) / 248.142
=0.00

HAEMATO AG's Capex-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.366) / 133.638
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HAEMATO AG  (XTER:HAEK) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


HAEMATO AG Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of HAEMATO AG's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


HAEMATO AG (XTER:HAEK) Business Description

Traded in Other Exchanges
Address
Lilienthalstrasse 5c, Schonefeld, DEU, D-12529
HAEMATO AG is a Germany based pharmaceutical company. It provides pharmaceuticals for the care of chronically ill people. The firm is engaged in the sale of generic and EU (European countries) import drugs. It is focused on patented and non-patented medicinal products. The company product portfolio includes human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), neurology, oncology, rheumatology, and urology. Geographically, it operates only in Germany.

HAEMATO AG (XTER:HAEK) Headlines

No Headlines